Concerns related to the nocebo effect

Affiliations

¹ Menzies Institute for Medical Research, Medical Science Precinct, Hobart, 7000 TAS, Australia. Electronic address: zhen.zhou@utas.edu.au.
² Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
³ Menzies Institute for Medical Research, Medical Science Precinct, Hobart, 7000 TAS, Australia.

Comment

Zhen Zhou et al. Lancet. 2017.

. 2017 Oct 21;390(10105):1831-1832.

doi: 10.1016/S0140-6736(17)32427-3. Epub 2017 Oct 19.

¹ Menzies Institute for Medical Research, Medical Science Precinct, Hobart, 7000 TAS, Australia. Electronic address: zhen.zhou@utas.edu.au.
² Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
³ Menzies Institute for Medical Research, Medical Science Precinct, Hobart, 7000 TAS, Australia.

No abstract available

Comment in

Concerns related to the nocebo effect - Authors' reply.
Gupta A, Godec T, Sever P. Gupta A, et al. Lancet. 2017 Oct 21;390(10105):1832. doi: 10.1016/S0140-6736(17)32423-6. Epub 2017 Oct 19. Lancet. 2017. PMID: 29082877 No abstract available.

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase.
Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P; ASCOT Investigators. Gupta A, et al. Lancet. 2017 Jun 24;389(10088):2473-2481. doi: 10.1016/S0140-6736(17)31075-9. Epub 2017 May 2. Lancet. 2017. PMID: 28476288 Clinical Trial.